Saluda Medical raises $75M for spinal cord stimulation

Saluda Medical acquired $75 million in equity financing from Boston Scientific and Redmile Group to fund the finishing stages of its Evoke evoked action compound potential-controlled, Closed-Loop Spinal Cord Stimulation System.

Advertisement

It is Saluda’s first device, designed for the treatment of chronic intractable pain of the trunk and limbs.

Existing shareholder Medtronic agreed a four-year loan deal with Saluda for the development of the device on June 27.

“This equity financing in combination with our recent debt transaction strategically positions us to fund the final developmental stages of the Evoke SCS System through global commercialization,” said John Parker, CEO of Saluda Medical. “We believe [Evoke] has immense potential for radically improving the way pain is treated.”

More articles on devices:
MicroPort Orthopedics launches knee system
Medtronic strikes loan agreement with Saluda Medical for spinal cord simulation study: 3 details
Dr. Zeeshan Sardar: 4 considerations when adapting a new spine device

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.